Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Overview
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (NASDAQ:URGN), reported the sale of 5,222 ordinary shares for a total of approximately $143,000, as disclosed in a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($27.30); post-transaction value based on the value of post-transaction holdings as reported in the Form 4.
Details
*1-year performance calculated as of June 12, 2026.
Source
Originally published at www.fool.com.
Related Articles
- Google Is Paying $920 Million Per Month to SpaceX. Here's Why Nvidia Is the Quiet Winner Nobody's Talking About.
- Interface's General Counsel Sold Company Stock Worth $1.3 Million. Here's a Deeper Look at the Transaction.
- Meet the E-Commerce Stock That's Up 25% in 2026. Is It a Better Buy Than Amazon?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
